FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890361884> ?p ?o ?g. }

• W2890361884 endingPage "835" @default.
• W2890361884 startingPage "824" @default.
• W2890361884 abstract "Background The use of medications to treat attention deficit hyperactivity disorder (ADHD) has increased, but the prevalence of ADHD medication use across different world regions is not known. Our objective was to determine regional and national prevalences of ADHD medication use in children and adults, with a specific focus on time trends in ADHD medication prevalence. Methods We did a retrospective, observational study using population-based databases from 13 countries and one Special Administrative Region (SAR): four in Asia and Australia, two in North America, five in northern Europe, and three in western Europe. We used a common protocol approach to define study populations and parameters similarly across countries and the SAR. Study populations consisted of all individuals aged 3 years or older between Jan 1, 2001, and Dec 31, 2015 (dependent on data availability). We estimated annual prevalence of ADHD medication use with 95% CI during the study period, by country and region and stratified by age and sex. We reported annual absolute and relative percentage changes to describe time trends. Findings 154·5 million individuals were included in the study. ADHD medication use prevalence in 2010 (in children aged 3–18 years) varied between 0·27% and 6·69% in the countries and SAR assessed (0·95% in Asia and Australia, 4·48% in North America, 1·95% in northern Europe, and 0·70% in western Europe). The prevalence of ADHD medication use among children increased over time in all countries and regions, and the absolute increase per year ranged from 0·02% to 0·26%. Among adults aged 19 years or older, the prevalence of any ADHD medication use in 2010 varied between 0·003% and 1·48% (0·05% in Asia and Australia, 1·42% in North America, 0·47% in northern Europe, and 0·03% in western Europe). The absolute increase in ADHD medication use prevalence per year ranged from 0·0006% to 0·12%. Methylphenidate was the most commonly used ADHD medication in most countries. Interpretation Using a common protocol and data from 13 countries and one SAR, these results show increases over time but large variations in ADHD medication use in multiple regions. The recommendations of evidence-based guidelines need to be followed consistently in clinical practice. Further research is warranted to describe the safety and effectiveness of ADHD medication in the short and long term, and to inform evidence-based guidelines, particularly in adults. Funding None The use of medications to treat attention deficit hyperactivity disorder (ADHD) has increased, but the prevalence of ADHD medication use across different world regions is not known. Our objective was to determine regional and national prevalences of ADHD medication use in children and adults, with a specific focus on time trends in ADHD medication prevalence. We did a retrospective, observational study using population-based databases from 13 countries and one Special Administrative Region (SAR): four in Asia and Australia, two in North America, five in northern Europe, and three in western Europe. We used a common protocol approach to define study populations and parameters similarly across countries and the SAR. Study populations consisted of all individuals aged 3 years or older between Jan 1, 2001, and Dec 31, 2015 (dependent on data availability). We estimated annual prevalence of ADHD medication use with 95% CI during the study period, by country and region and stratified by age and sex. We reported annual absolute and relative percentage changes to describe time trends. 154·5 million individuals were included in the study. ADHD medication use prevalence in 2010 (in children aged 3–18 years) varied between 0·27% and 6·69% in the countries and SAR assessed (0·95% in Asia and Australia, 4·48% in North America, 1·95% in northern Europe, and 0·70% in western Europe). The prevalence of ADHD medication use among children increased over time in all countries and regions, and the absolute increase per year ranged from 0·02% to 0·26%. Among adults aged 19 years or older, the prevalence of any ADHD medication use in 2010 varied between 0·003% and 1·48% (0·05% in Asia and Australia, 1·42% in North America, 0·47% in northern Europe, and 0·03% in western Europe). The absolute increase in ADHD medication use prevalence per year ranged from 0·0006% to 0·12%. Methylphenidate was the most commonly used ADHD medication in most countries. Using a common protocol and data from 13 countries and one SAR, these results show increases over time but large variations in ADHD medication use in multiple regions. The recommendations of evidence-based guidelines need to be followed consistently in clinical practice. Further research is warranted to describe the safety and effectiveness of ADHD medication in the short and long term, and to inform evidence-based guidelines, particularly in adults." @default.
• W2890361884 created "2018-09-27" @default.
• W2890361884 creator A5006777946 @default.
• W2890361884 creator A5014914035 @default.
• W2890361884 creator A5015054278 @default.
• W2890361884 creator A5021145561 @default.
• W2890361884 creator A5021605461 @default.
• W2890361884 creator A5021887793 @default.
• W2890361884 creator A5022338649 @default.
• W2890361884 creator A5025936391 @default.
• W2890361884 creator A5026171124 @default.
• W2890361884 creator A5028633730 @default.
• W2890361884 creator A5029141684 @default.
• W2890361884 creator A5029284712 @default.
• W2890361884 creator A5032966646 @default.
• W2890361884 creator A5032986176 @default.
• W2890361884 creator A5036291591 @default.
• W2890361884 creator A5043069598 @default.
• W2890361884 creator A5044865490 @default.
• W2890361884 creator A5051403615 @default.
• W2890361884 creator A5051519595 @default.
• W2890361884 creator A5054223673 @default.
• W2890361884 creator A5054341731 @default.
• W2890361884 creator A5055912652 @default.
• W2890361884 creator A5058616004 @default.
• W2890361884 creator A5062381819 @default.
• W2890361884 creator A5065558451 @default.
• W2890361884 creator A5068646928 @default.
• W2890361884 creator A5072859924 @default.
• W2890361884 creator A5075102424 @default.
• W2890361884 creator A5076676344 @default.
• W2890361884 creator A5077702002 @default.
• W2890361884 creator A5079729727 @default.
• W2890361884 creator A5086208075 @default.
• W2890361884 creator A5086353678 @default.
• W2890361884 date "2018-10-01" @default.
• W2890361884 modified "2023-10-17" @default.
• W2890361884 title "Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases" @default.
• W2890361884 cites W1784564451 @default.
• W2890361884 cites W1925265025 @default.
• W2890361884 cites W1983030849 @default.
• W2890361884 cites W1997172059 @default.
• W2890361884 cites W1997598370 @default.
• W2890361884 cites W2007817385 @default.
• W2890361884 cites W2016511885 @default.
• W2890361884 cites W2018684776 @default.
• W2890361884 cites W2023351650 @default.
• W2890361884 cites W2045691626 @default.
• W2890361884 cites W2057670386 @default.
• W2890361884 cites W2079992788 @default.
• W2890361884 cites W2104582464 @default.
• W2890361884 cites W2107328434 @default.
• W2890361884 cites W2114290463 @default.
• W2890361884 cites W2117104588 @default.
• W2890361884 cites W2126271209 @default.
• W2890361884 cites W2127901933 @default.
• W2890361884 cites W2137706707 @default.
• W2890361884 cites W2160610591 @default.
• W2890361884 cites W2162012775 @default.
• W2890361884 cites W2168001527 @default.
• W2890361884 cites W2171074660 @default.
• W2890361884 cites W2186549343 @default.
• W2890361884 cites W2511866207 @default.
• W2890361884 cites W2559104384 @default.
• W2890361884 cites W2597501992 @default.
• W2890361884 cites W2614669943 @default.
• W2890361884 cites W2735057791 @default.
• W2890361884 cites W2765395469 @default.
• W2890361884 cites W2914686075 @default.
• W2890361884 doi "https://doi.org/10.1016/s2215-0366(18)30293-1" @default.
• W2890361884 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30220514" @default.
• W2890361884 hasPublicationYear "2018" @default.
• W2890361884 type Work @default.
• W2890361884 sameAs 2890361884 @default.
• W2890361884 citedByCount "166" @default.
• W2890361884 countsByYear W28903618842018 @default.
• W2890361884 countsByYear W28903618842019 @default.
• W2890361884 countsByYear W28903618842020 @default.
• W2890361884 countsByYear W28903618842021 @default.
• W2890361884 countsByYear W28903618842022 @default.
• W2890361884 countsByYear W28903618842023 @default.
• W2890361884 crossrefType "journal-article" @default.
• W2890361884 hasAuthorship W2890361884A5006777946 @default.
• W2890361884 hasAuthorship W2890361884A5014914035 @default.
• W2890361884 hasAuthorship W2890361884A5015054278 @default.
• W2890361884 hasAuthorship W2890361884A5021145561 @default.
• W2890361884 hasAuthorship W2890361884A5021605461 @default.
• W2890361884 hasAuthorship W2890361884A5021887793 @default.
• W2890361884 hasAuthorship W2890361884A5022338649 @default.
• W2890361884 hasAuthorship W2890361884A5025936391 @default.
• W2890361884 hasAuthorship W2890361884A5026171124 @default.
• W2890361884 hasAuthorship W2890361884A5028633730 @default.
• W2890361884 hasAuthorship W2890361884A5029141684 @default.
• W2890361884 hasAuthorship W2890361884A5029284712 @default.
• W2890361884 hasAuthorship W2890361884A5032966646 @default.
• W2890361884 hasAuthorship W2890361884A5032986176 @default.
• W2890361884 hasAuthorship W2890361884A5036291591 @default.
• W2890361884 hasAuthorship W2890361884A5043069598 @default.

• next